Price$5.00-1.67 (-24.98%)
2026-07-162026-10-16
News · 26 weeks37+400%
2026-04-192026-10-11
Mix2390d
- Insider10(43%)
- SEC Filings5(22%)
- Other4(17%)
- Earnings2(9%)
- Offering1(4%)
- Analyst1(4%)
Latest news
25 items- PRDarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare CostsA component study of the independent review by Aon found $5,077 in annual savings and 23.5% fewer inpatient discharges per Dario user with type 2 diabetes versus matched non-usersEvaluation of 17 studies estimates $3.8 million to $10.8 million in annual savings for a 20,000-life population Aon estimates an additional 1.6 to 2.8 percentage points of potential healthcare cost savings as a result of providing direct access to physicians while simultaneously managing multiple chronic conditions, for potential total of 10% annual savings Independent analysis finds that evidence supports the economic value of Dario's multi-condition digital health platform for payers including employers, health pl
- INSIDERDirector Shaked Yoav converted options into 772 shares and was granted 54,000 shares, increasing direct ownership by 167% to 87,582 units (SEC Form 4)4 - DarioHealth Corp. (0001533998) (Issuer)
- INSIDERDirector Mcgrath Dennis M was granted 61,000 shares, increasing direct ownership by 220% to 88,737 units (SEC Form 4)4 - DarioHealth Corp. (0001533998) (Issuer)
- INSIDERDirector Palumbo John R was granted 62,000 shares, increasing direct ownership by 1,378% to 66,500 units (SEC Form 4)4 - DarioHealth Corp. (0001533998) (Issuer)
- INSIDERDirector Stern Adam K converted options into 20,195 shares and was granted 28,000 shares, increasing direct ownership by 94% to 57,717 units (SEC Form 4)4 - DarioHealth Corp. (0001533998) (Issuer)
- INSIDERDirector Matheis Dennis was granted 44,000 shares, increasing direct ownership by 102% to 87,026 units (SEC Form 4)4 - DarioHealth Corp. (0001533998) (Issuer)
- INSIDERChief Financial Officer Franco-Yehuda Chen was granted 95,000 shares, increasing direct ownership by 317% to 125,000 units (SEC Form 4)4 - DarioHealth Corp. (0001533998) (Issuer)
- INSIDERDirector Karah Hila was granted 28,000 shares, increasing direct ownership by 90% to 58,965 units (SEC Form 4)4 - DarioHealth Corp. (0001533998) (Issuer)
- INSIDERChief Executive Officer Raphael Erez converted options into 579 shares and was granted 297,000 shares, increasing direct ownership by 190% to 454,432 units (SEC Form 4)4 - DarioHealth Corp. (0001533998) (Issuer)
- INSIDERNew insider Sherman Lara Ann claimed ownership of 120,000 shares (SEC Form 3)3 - DarioHealth Corp. (0001533998) (Issuer)
- PRDario Wins Contract with One of New Jersey's Largest Health Plans Representing 1.5 Million Covered LivesAgreement secured through channel partner Amwell significantly expands Dario's reach through its channel distribution strategyProgram for Dario's cardiometabolic suite and provider-backed care expected to launch with the customer and begin generating revenue in the first quarter of 2027Marks the third large state health plan signed through Amwell in the past 12 months, following contracts in Arizona and FloridaNEW YORK, Sept. 17, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced a new contract with a leading health plan in New Jer
- SECDarioHealth Corp. filed SEC Form 8-K: Leadership Update8-K - DarioHealth Corp. (0001533998) (Filer)
- SECDarioHealth Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - DarioHealth Corp. (0001533998) (Filer)
- ANALYSTAlliance Global Partners initiated coverage on DarioHealth with a new price targetAlliance Global Partners initiated coverage of DarioHealth with a rating of Buy and set a new price target of $12.00
- PRDarioHealth Reports Second Quarter 2026 Financial ResultsSecond quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related businessGross margin increased to 62%, compared to 57% in the first quarter of 2026 and 55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately 80% for the 10th consecutive quarterOperating loss decreased by 30% year-over-year and 11% quarter-over-quarterOperating expenses declined by 21% year-over-year and 8% quarter-over-quarterMulti-condition strategy compounding: more than 80% of the $13.1 million in contracted and late-stage annual recurring revenue ("ARR") is multi-conditionCommercial momentum with three significant wins in rec
- SECSEC Form 10-Q filed by DarioHealth Corp.10-Q - DarioHealth Corp. (0001533998) (Filer)
- PRDario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client DemandNew programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company's provider-backed care strategyAI-enabled programs combine digital engagement, human behavioral coaching and clinical care to improve outcomes while expanding Dario's participation in reimbursement-driven healthcare servicesNEW YORK, Aug. 4, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced it has further expanded its provider-backed cardiometa
- PRDarioHealth to Report Second Quarter 2026 Results on Tuesday, August 11, 2026Company to host conference call and webcast at 8:30 a.m. Eastern TimeNEW YORK, Aug. 3, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leading artificial intelligence ("AI")-powered healthcare technology company transforming the management of chronic conditions, announced today that it will release its financial results for the 2nd quarter ended June 30th, 2026 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Tuesday, August 11th, 2026, before the market opens. Erez Raphael, Chief Executive Officer, Lara Dodo, Chief Operations Officer, and Chen Franco-Yehuda, Chief Financial Officer, will host the call.Conference Call DetailsDate: T
- PRDario Launches Integrated GLP-1 Program, Combining Its Digital Chronic Care Platform with Provider-Backed Clinical Care in a Single End-to-End ExperienceFirst commercial offering from Dario's collaboration with Beluga Health adds licensed provider evaluation, prescribing and ongoing clinical oversight directly inside Dario's chronic care platform Commercial availability expected Fall 2026, with revenue contribution anticipated late 2026 and ramping through 2027 Launch addresses a market in which employers and health plans are reducing GLP-1 coverage and members are increasingly accessing care through consumer channels Available through three channels: Dario's direct-to-consumer shop, health plan marketplaces and employer B2B2C programs NEW YORK, July 30, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" o
- INSIDERDirector Matheis Dennis converted options into 965 shares and bought $100,000 worth of shares (14,430 units at $6.93), increasing direct ownership by 56% to 43,026 units (SEC Form 4)4 - DarioHealth Corp. (0001533998) (Issuer)
- SECDarioHealth Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - DarioHealth Corp. (0001533998) (Filer)
- SECSEC Form 424B5 filed by DarioHealth Corp.424B5 - DarioHealth Corp. (0001533998) (Filer)
- PRDario Announces Pricing of a $23.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq RulesThe financing was led by continued support of existing long-term institutional investors along with participation from a new global fundamental institutional investorNEW YORK, July 22, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company," "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced that it has entered into securities purchase agreements with current long term Dario institutional investors as well as new fundamental investors for the purchase and sale of 3,454,559 shares of common stock (or common stock equivalents in lieu thereof), at a price of $6.80 per share, in a registered
- PRFortune 50 Employer Awards Dario Contract to Deliver AI-Powered Cardiometabolic Care PlatformContract award for over 100,000 eligible employees marks Dario's fifth Fortune 50 client, further reflecting growing demand among large employers for integrated, outcomes-driven chronic condition managementProgram expected to launch Fall 2026, with revenue contribution beginning by year-end and ramping through 2027NEW YORK, July 16, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced another Fortune 50 employer has selected Dario to provide its integrated digital cardiometabolic care platform for employees living with diabetes and/o
- PRDario Expects Proprietary AI Engine DarioIQ™ to Increase Recurring Revenue from Existing Customers by 10-15%DarioIQ drives higher engagement and retention, better clinical outcomes, higher client ROI and recurring revenue growth for DarioDario IQ's AI-driven personalization increases member engagement by 40% and improves member retention by 20% by leveraging 13+ billion proprietary real-world healthcare data pointsNEW YORK, July 13, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company," "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced the Company expects broader deployment of DarioIQ™, its proprietary, responsible generative and agentic AI platform, to increase annual Business-to-Business-
DRIO FAQ
6 questionsWhat does DarioHealth Corp. do?
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario Tools, which are devices that integrate with applications on a user's smartphone; DarioEngage, a population health management platform; and the Dario Loop, an AI-driven journey engine. It also sells device-specific disposables test strip cartridges, lancets, and Dario Blood Glucose Monitoring System; and Dario Smart Diabetes Management Solution, which includes tools to help diabetic patients manage their disease. The company was...Where does DRIO stock trade?
DarioHealth Corp. (DRIO) is listed on NASDAQ.What sector and industry is DRIO in?
DarioHealth Corp. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about DRIO?
DarioHealth Corp. has had 5 recent analyst actions on file. The most recent action was from Alliance Global Partners: Buy with a $1200.00 price target on 2026-08-19.What companies are similar to DRIO?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare DRIO side-by-side with any of them on Quantisnow.How can I track DRIO on Quantisnow?
Quantisnow aggregates DarioHealth Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DRIO to receive live email and push alerts on every new disclosure.